Effect of covid-19 vaccine (Pfizer) on ANbs, IgG serum levels for uninfected and previous infected individuals

ABSTRACT

Background: The World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a public health emergency on January 30, 2020. Mass vaccination programs are needed to boost population immunity and prevent COVID-19 pandemic impacts. In this research, we used the Pfizer BioNTech vaccine, which Iraqis prefer above others. Pfizer and BioNTech's BNT162b2 was 95% effective in preventing COVID-19 symptoms and almost 100% effective at preventing severe COVID-19 or hospitalizations, and the US FDA authorized its first EUA on December 11, 2020. Methods: This cohort study was conducted in Al-Manathira Health Center in Al-Najaf Al-Ashraf Governorate from (October 2021 to May 2022). 75 samples (55 males and 20 females) with or without previous infections were collected, and these samples were divided into five groups according to age (18-50 and over). We collected three venous blood samples from the vaccinated. Results: A serological analysis to measure SARS-CoV-2 S1 -RBD IgG and neutralizing antibodies NAbs to SARS-CoV-2 was done by using the CLIA technique SARS-CoV-2 kits, China, which was carried out in the Najaf Specialized Laboratory for Pathological Analysis. In this study, neutralizing antibody (NAbs) and immunoglobulin G (IgG) levels after two doses of Pfizer/BioNTech vaccine increased at a level of 0.05 (p = 0.00001). Conclusions: This study concluded that there were high and gradually increasing concentrations of neutralizing antibodies (NAbs) and IgG after two doses of the Pfizer/BioNTech vaccine. © 2022, ResearchTrentz Academy Publishing Education Services. All rights reserved.